The bill outlines the establishment of the Rhode Island Drug Cost Review Commission (DCR Commission) as a new entity under Chapter 19.3 in Title 5 of the General Laws. The commission aims to tackle high prescription drug costs in Rhode Island, drawing inspiration from Canada's national drug price review board. It will consist of five members with relevant expertise, appointed by state leaders, and supported by a 13-member advisory board representing various stakeholders. The commission will have the authority to hire staff, conduct public meetings, and review drug product information submissions. New legal language is inserted to define terms such as "excess costs" and "working acquisition costs" (WAC), and to outline the commission's organization, hiring practices, and operations.

The bill mandates that drug manufacturers notify the commission of significant price increases or the introduction of high-cost drugs, providing a detailed justification at least 30 days in advance. The commission will hold public reviews and votes on cost or payment limits and will determine if a drug leads to excess costs for the state's healthcare system. If a drug is deemed to create excess costs, the commission will set reimbursement levels for various stakeholders. Non-compliance with these levels may result in legal action by the attorney general. The bill includes provisions for appeals, commission financing, and annual reporting, and will be enforced by the attorney general upon passage. An advisory board will be established to support the commission's work. There are no specific deletions mentioned in the summary provided.